How close are we to preventing prostate cancer?
Peter T Scardino
This article has no abstract so we have provided the first paragraph of the full text.
Some years ago the legendary Paul Peters, then Secretary of the American Urological Association (AUA), liked to taunt his audience, warning that urologists sit on a three-legged stool—prostate cancer, BPH and bladder cancer—only three drugs away from oblivion as a surgical specialty. While there are no such drugs for bladder cancer, drug therapy for BPH has had a profound impact on urological practice. Alpha-blockers and 5-
reductase inhibitors (5RIs) allow most patients to delay or completely avoid invasive therapy. Transurethral resection of the prostate, once the most common operation performed by urologists in the US, fell from 258,000 procedures per year in 1987 to 87,000 in 2000.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.